Rockland Immunochemicals, Inc. offers each academic, biopharma, and diagnostic professional thousands of antibodies with the aim of providing the right antibody that is the perfect fit for every occasion. No matter the context – basic research to disease therapy, phosphorylated to methylated and beyond – Rockland embraces the challenge to design, produce, validate, and deliver the absolute best antibodies and life science reagents available in the market today and every day. With Rockland, your solution is complete.
SECTOR: Devices
SUB SECTOR: Drug Delivery
SPECIALITY: Drug Delivery
Rockland Immunochemicals, Inc. offers each academic, biopharma, and diagnostic professional thousands of antibodies with the aim of providing the right antibody that is the perfect fit for every occasion. No matter the context – basic research to disease therapy, phosphorylated to methylated and beyond – Rockland embraces the challenge to design, produce, validate, and deliver the absolute best antibodies and life science reagents available in the market today and every day. With Rockland, your solution is complete.
Rockland Immunochemicals, Inc. offers each academic, biopharma, and diagnostic professional thousands of antibodies with the aim of providing the right antibody that is the perfect fit for every occasion. No matter the context – basic research to disease therapy, phosphorylated to methylated and beyond – Rockland embraces the challenge to design, produce, validate, and deliver the absolute best antibodies and life science reagents available in the market today and every day. With Rockland, your solution is complete.
Our laboratories have been in Pennsylvania for over fifty-five years. Our collaborators work in the premier research institutions and companies around the world. Our antibodies have been put to conceivable use – tested and characterized again and again.
Rockland makes antibodies everyday — polyclonal, monoclonal, VHH single domain, primary, secondary, pre-adsorbed, conjugated, affinity purified, F(c), F(ab’)2 and Fab fragments. It’s our passion. Proudly, Rockland is the pioneer and leading expert in secondary antibodies. Diversity, specificity, stability, consistency, and reliability are the hallmarks of Rockland secondary antibodies. The work horse in every assay, our secondary antibodies detect, control, block, enrich, visualize, neutralize, precipitate, and discover.
Our staff agrees that your experiments are of the utmost importance, and that’s why our products do not leave our facility until they pass our rigorous barrage of quality control tests. Our scientists validate the performance of antibodies by assays commonly used by most researchers including ELISA, western blotting and immunohistochemistry. Some companies rely on you, the scientist, to perform their quality control testing! Not so at Rockland. Because we produce our own antiserum at our animal facilities and purify and test each antibody in our laboratories, we can guarantee the quality of every product we make. Furthermore, each product line is multi-assay validated to ensure uncompromised research conditions.
Rockland adheres to QSR / cGMP quality standards (CFR:21H part 820) with full reporting and traceability. We perform rigorous quality control testing procedures for everything that leaves our facility, whether it is a catalog product or a custom produced solution. These tests include Enzyme-linked immunosorbent assay (ELISA), Western Blot, Immunofluorescence microscopy, frozen section Immunohistochemistry, paraffin embed formalin fixed Immunohistochemistry, High-performance liquid chromatography (HPLC), Size Exclusion Chromatography (SEC), antibody conjugation and fragmentation, bioburden assays, and both one dimensional and two dimensional (1D and 2D) sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Rockland products are guaranteed to give predictable, repeatable results. We are one of the most referenced companies in the industry and continue to collaborate to develop products such as isoform specific AKT antibodies, GFP and RFP antibodies, and fluorochrome conjugated secondary antibodies validated by the most demanding assays.
Rockland is an internationally acclaimed manufacturer and trusted partner. We take pride in our products and stand as the leader in antibody innovation.
With over 6,000 products, we offer the most comprehensive selection of antibodies available. By creating our antibodies in-house, our products are guaranteed to give predictable, repeatable results. Protect your experiments with Rockland antibodies. Compromise elsewhere.
Primary antibodies are developed to specifically detect a particular antigen of interest.
Secondary antibodies bind to the primary antibody to assist in detection, sorting and purification of target antigens.
Rockland offers a variety of antibodies to be used as markers of protein localization, purification of recombinant proteins, tag detection and signal amplification.
Peptides are small polymers of amino acid monomers that are bonded together and distinguished from proteins by their size (typically containing fewer than 50 monomer units). Peptides allow the development of antibodies of a very specific region of a protein without the need to purify the protein of interest. They also allow for the identification of proteins of interest based on peptide masses and sequence. Typically, peptides are used in clinical research to examine the inhibition of cancer proteins and other diseases.
Rockland kits contain an assortment of required antibodies (primary antibodies, secondary antibodies, or types of conjugated antibodies for specific detection), substrates, and any other required component for a specific experiment.
To reduce variables in any type of experiment it is advisable to include both positive and negative controls in the experimental design.
Rockland produces a number of blood products to meet a variety of research goals.
Rockland offers control cell lysates and nuclear extracts for use on SDS PAGE as standalone samples or in combination with antibodies on Western Blotting experiments.
Rockland offers supporting reagents to facilitate various immunoassays including Blocking Solutions, BSA and Enzyme Substrates.
Rockland Immunochemicals has been providing products and services to the University and Corporate Research Community for over 50 years. Rockland's Custom Services provide high quality price competitive services and packages.
Rockland’s product portfolio provides well characterized and sensitive generic reagents for immunodetection of host cell proteins as well as multiple customizable options for process-specific HCP antibody development as a service.
Rockland’s growing suite of molecular biology custom products and services will help accelerate your studies whether working on basic research or performing advanced translational studies.
Rockland's full-service immunoassay development service bridges the path from discovery to product.
Rockland has decades of experience in conjugation of antibody and protein reagents.
Rockland offers a variety of purification services for the purification of native and recombinant proteins, as well as for antibodies (including fragments and modified proteins).
Rockland’s experience in working with antibody enzymatic cleavage allows us to process immunoglobulins into their constituent components.
Rockland's Immunohistochemistry Studies (IHC) provide confidential high-quality target localization data through its extensive services.
Rockland has been serving the scientific and IVD community for over 50 years and believes that the quality of raw materials are of the utmost importance in the successful development and manufacturing of In-vitro Diagnostic (IVD) products.
Rockland Immunochemicals custom peptide synthesis service provides synthetic peptides that include a broad range of labels, modifications, scales, purities and delivery time options.
Rockland provides users the technological resource and technical assistance for high quality, multi-parameter flow cytometry analyses and sorting.
Rockland can assist you in the chemical synthesis of your target analytes; chemical compounds such as drugs, drug metabolites, mycotoxins, steroids and other bioactive substances (haptens).
Rockland provides mass spectrometry (MS) analysis of proteins and peptides at maximum sensitivity using state-of-the-art instruments and methods.
Rockland offers a growing portfolio of analytical capabilities for routine determination of purity, aggregation, size variant analysis and charged-based separations of antibodies and other proteins to be used in sensitive applications.
Snapshot Proteomics™ uses microarrays that contain approximately 20,000 individual human proteins
At Rockland, our experience and capabilities enable us to provide customized services to meet our client's needs.
Limerick, PA. September 4, 2018 – Rockland Immunochemicals, Inc. announced today the general release of their new BioQuantiPro™ CHO-HCP ELISA Kit for detection and screening of host cell protein (HCP) contaminants in bioprocessing. The kit was specifically designed with Rockland’s novel, validated antibodies to detect HCP contaminants and to measure analytes from crude cellular harvests, cell culture lysates, and process intermediates. The BioQuantiPro CHO-HCP ELISA Kit boasts the highest coverage of generic CHO-HCP kits, low variability, and, most importantly, the data to back it all up.
Rockland Immunochemicals Inc. in Limerick Township, Montgomery County, is part of the foundations in that research. It develops antibodies, substrates and other chemicals for biotech research and testing.
Limerick, PA. November 14th, 2016 – Rockland Immunochemicals, Inc. (Rockland) announced today the award of a $299,625 Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) to develop bispecific single chain recombinant antibodies for pre-targeted cancer diagnostic imaging and treatment. The funds will be distributed among Rockland and its collaborators, Abzyme Therapeutics (Limerick, PA) and Dr. Carolyn Anderson of the University of Pittsburgh Medical Center (Pittsburgh, PA). This joint strategic effort will promote the generation of novel reagents and new insights for cancer imaging and therapeutic research.
Limerick, PA. September 8th, 2014 – Rockland Immunochemicals, Inc. (Rockland) announced today the award of a $224,473 Small Business Innovation Research (SBIR) grant from the NIH National Heart Lung and Blood Institute (NHLBI) to develop an antibody-based point of care device for the diagnosis of Sickle Cell Disease (SCD), a mutation that is carried in approximately 7% of the world’s population. Rockland secured the award by demonstrating the technology and processes it deploys to develop and to produce leading edge life science tools for basic and clinical research focused on functional genomics and drug discovery markets.
UK based specialist diagnostic manufacturer, The Binding Site Group Ltd, is pleased to announce that it has entered into an exclusive, definitive agreement with Rockland Immunochemicals, Inc., of Limerick, PA, to grant Rockland global distribution rights for Binding Site’s line of animal-focused radial immunodiffusion (RID) test kits. The availability of this unique range of products exclusively through Rockland will benefit the needs of laboratory professionals conducting basic, applied, and clinical research in the veterinary, biomedical, life-science, genomics, and drug discovery fields.
In a continuing effort in the fight against childhood cancer, Rockland awarded the Joy Cappel Young Investigator Award (JCYIA) to two Alex’s Lemonade Stand Foundation (ALSF) Young Investigator grantees. In addition, Rockland is donating over $150,000 in reagents for the projects of ALSF Young Investigator and ‘A’ Award grantees with active grants.
Berwyn, PA, and Limerick, PA – February 22, 2016 – Formula Pharmaceuticals, Inc. and Rockland Immunochemicals, Inc. announced today the establishment of a collaboration for the preclinical development of Formula’s Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) cancer immunotherapies at Rockland’s R&D facility. Under the collaboration, Rockland will provide and manage Formula’s specially hired preclinical research team. Further, Rockland will provide the classified research facilities for Formula’s preclinical development needs in its newly established, scalable 60,000 sq ft R&D facility.
Gilbertsville, PA. January 20th, 2014 – Rockland Immunochemicals Inc. today announced that it donated $6,700 to Breastcancer.org, based on the sales of “Pink products”. In October 2013, Rockland declared seven groups of products “pink” in an effort to support Breast Cancer Awareness Month. These product categories included a variety of conjugates, ATTO dyes and protein markers.
September 14, 2015, Limerick, Pa. – On September 9th, Rockland Immunochemicals, Inc., conducted an event with leading representatives spanning Government, Non-Profit, Industry and Education. Attendees included Pennsylvania State Senator Bob Mensch, State Representative Tom Quigley, John Munera of State Senator John Rafferty, Jr.’s office, and officials from The Wistar Institute, Montgomery County Community College (MCCC), and PABio.
Limerick, PA. May 28, 2014 – Rockland Immunochemicals, Inc. expands laboratories to address increased demand for life science research tools. Recognizing the increased demand in its core business segments – antibody products and services - Rockland began planning for its new facility in 2012.
Limerick, PA. April 7th, 2014 – Rockland Immunochemicals Inc. today announced a new annual award will be given to promising young investigators including graduate students, post-doctoral fellows, or other young scientists. This award is intended to help young investigators establish themselves in the areas of oncology, nuclear signaling, developmental biology, epigenetics, immunology, microbiology, neuroscience, signal transduction or stem cell technology. For each of the next ten years, Rockland is awarding $100,000 in total to twenty-five qualified candidates.
Limerick, PA. February 1st, 2016 – Rockland Immunochemicals, Inc. (Rockland) announced today, the availability of a new collection of human been developed and characterized over several decades in the lab of Dr. Meenhard Herlyn, D.V.M., D. Sci., Caspar Wistar Professor in Melanoma Research, Director of the Melanoma Research Center, and professor in the Molecular and Cellular Oncogenesis Program at The Wistar Institute. Over one hundred of these human melanoma cell lines will now be grown and exclusively distributed by Rockland. This new agreement comes as the first development from the institutions’ new partnership, announced in July 2015.
CEDARVILLE Engineering Group, LLC, (CEDARVILLE) and Rockland Immunochemicals, Inc., today announced a research collaboration designed to explore the development of innovative applications in 3D bioprinting that will advance life science research and accelerate the drug discovery process. Interest in 3D bioprinting has emerged in recent years. Applications for 3D bioprinting include drug screening, precision and regenerative medicine, food products and biosensors. The project is expected to leverage the expertise CEDARVILLE has in 3D modeling and printing, and the insight Rockland has in developing cutting-edge reagents and cell culture processes critical to novel biotechnologies.
Limerick, PA. November 17th, 2014 – Rockland Immunochemicals Inc. today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH). Rockland will use the grant to develop synthetic antibodies for detection and quantitation of modified RNAs.
Limerick, PA. January 28th, 2015 – Rockland Immunochemicals Inc. today announced that it has acquired a minority interest in Abzyme Therapeutics, LLC (Abzyme). Abzyme’s unique technology, designed to develop therapeutic antibodies, comes as an interest to Rockland after the two companies worked together on several former and ongoing National Institute of Health (NIH) funded projects.
Limerick, PA. August 9, 2018 – Rockland Immunochemicals, Inc. announced today that Dr. Carl Ascoli, Chief Science Officer at Rockland, and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, composed a peer-reviewed article using their combined experience of more than 50 years.
